rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
R132H mutation of isocitrate dehydrogenase 1 (IDH1) is found in ~75% of low-grade gliomas and secondary glioblastomas as well as in several other types of cancer.
|
29792149 |
2018 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A clonal IDH1 R132H mutation in the primary, a known GBM driver event, was detectable at only very low frequency in the recurrent tumour.
|
25732040 |
2015 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A total of 15.3% of enrolled GBMs demonstrated loss of ATRX expression (ATRX-), 10.4% expressed an aberrant IDH1 R132H protein (IDH1+), and 48.4% exhibited p53 overexpression (p53+).
|
27478330 |
2016 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Among the GBM cases it was noted that the IDH1 immunopositive tumors (R132H mutant protein; n=17) had a low MnSOD expression as opposed to IDH1 immunonegative tumors (n=106), which had high expression of MnSOD (p=0.0307).
|
26616112 |
2016 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Data showed that 53.7% (72/134) of cases showed mutations affecting codon 132 of IDH1, including 73.2% of LOs, 82.9% of AOs and three primary GBMs (6.5%).All IDH1 mutations were Arg132His.
|
22922798 |
2012 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation.
|
23011765 |
2013 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
For this reason, it was suggested that immunohistochemistry against IDH1 R132H is sufficient to classify GBM as IDH wild-type in this age group.
|
31758617 |
2020 |
rs121913499
|
|
Glioblastoma
|
|
0.710 |
GeneticVariation
|
BEFREE |
Furthermore, SMab-1 specifically stained the IDH1-R132S-expressing glioblastoma cells in immunocytochemistry and immunohistochemistry, but did not react with IDH1-WT or IDH1-R132H-containing glioblastoma cells.
|
21352804 |
2011 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Furthermore, SMab-1 specifically stained the IDH1-R132S-expressing glioblastoma cells in immunocytochemistry and immunohistochemistry, but did not react with IDH1-WT or IDH1-R132H-containing glioblastoma cells.
|
21352804 |
2011 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here we show that SREBPs were up-regulated in U87 human glioblastoma cells transfected with an IDH1(R132H)-expression plasmid.
|
24077277 |
2013 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
HMab-2 detected endogenous IDH1-R132H protein expressed in glioblastoma in immunohistochemical analysis.
|
26381180 |
2015 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In addition, overexpression of IDH1-R132H in glioblastoma cell lines U87 and U251 led to reduced cell proliferation, migration and invasion, accompanied by increased apoptosis.
|
26860959 |
2016 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In the subgroup of 142 glioma patients characterized by IDH1-R132H status, METT/N ratio demonstrated a significant prognostic impact in IDH1-R132H wildtype astrocytomas and glioblastoma (P = 0.001).
|
29016947 |
2018 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this study, we investigated which genes are differentially regulated in IDH1 wild type (IDH1WT) or IDH1 R132H mutation (IDH1R132H) glioblastoma cells.
|
28445981 |
2017 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Induction of G-CIMP+ state by exogenous expression of a mutated isocitrate dehydrogenase 1, IDH1-R132H, suppressed EGFR and H-Ras protein expression as well as pERK accumulation in independent glioblastoma models.
|
25277177 |
2014 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Isocitrate dehydrogenase (IDH) is mutated in >80% of lower-grade infiltrating gliomas in adults and in ~10% of glioblastomas, with IDH1 (R132H) being the most common mutation.
|
30221786 |
2019 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Isocitrate dehydrogenase 1 (IDH1) gene mutations, primarily of the R132H type, occur in approximately 60 - 90% of diffuse and anaplastic gliomas and secondary glioblastomas.
|
21955925 |
2011 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Low-grade gliomas (WHO II/III) had lower xCT expression than glioblastoma (p = 0.001), and tumors without IDH1 R132H mutation tended to have higher xCT levels (p = 0.07).
|
29404978 |
2018 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide.
|
28571041 |
2017 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Multivariate analysis revealed age, Karnofsky performance score, extent of tumor resection, first-line treatment, year of diagnosis, and MGMT promoter methylation status were associated with survival in patients with IDH1(R132H) -nonmutant glioblastoma.
|
27088883 |
2016 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutated IDH1 R132H protein and H3F3A K27M mutations indicate that a substantial number of GBMc are "metastatic" or "diaschismatic" lesions.
|
30203362 |
2018 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutation of the isocitrate dehydrogenase 1 (IDH1) gene at codon 132 has been identified in approximately 70% of low-grade (II and III) human gliomas and secondary glioblastomas, with the IDH1 R132H point mutation representing 92.7% of these mutations.
|
30502793 |
2018 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results indicate that the IDH1 R132H mutation is a powerful prognostic marker in GBM treated with chemoradiation.
|
20560678 |
2010 |
rs121913500
|
|
Glioblastoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results suggest that the pathogenesis of multicentric gliomas is different from the mutant IDH1-R132H pathogenesis of lower-grade glioma and secondary glioblastomas.
|
27553586 |
2017 |